The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).
 
Weijun Fu
No Relationships to Disclose
 
Zhongjun Xia
No Relationships to Disclose
 
Chengcheng Fu
Consulting or Advisory Role - BeiGene; Janssen; Takeda
Speakers' Bureau - BeiGene; Janssen; Pfizer; Roche; Sanofi; Takeda
 
Wenming Chen
No Relationships to Disclose
 
Gang An
No Relationships to Disclose
 
Zhen Cai
No Relationships to Disclose
 
Baijun Fang
No Relationships to Disclose
 
Hongmei Jing
No Relationships to Disclose
 
Yongqiang Wei
No Relationships to Disclose
 
Jianyu Weng
No Relationships to Disclose
 
Chunkang Chang
No Relationships to Disclose
 
Lijuan Chen
No Relationships to Disclose
 
Sujun Gao
No Relationships to Disclose
 
Xiequn Chen
No Relationships to Disclose
 
Fei Li
No Relationships to Disclose
 
Zhuogang Liu
No Relationships to Disclose
 
Jing Liu
No Relationships to Disclose
 
Ying Jiao
Employment - Antengene
 
Aihua Wang
Employment - Antengene
Stock and Other Ownership Interests - Antengene
 
Lugui Qiu
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene
Speakers' Bureau - Amgen; BeiGene; Johnson & Johnson; Takeda
Research Funding - BeiGene (Inst)